Cassava sciences inc (SAVA)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash flows from operating activities:
Net loss

-4,631

-6,557

-11,911

-14,850

-14,145

-12,386

31,544

-3,446

-2,613

-12,023

-3,467

Adjustments to reconcile net loss to net cash used in operating activities:
Deferred program fee revenue

-

-

-

-

-

-

41,119

10,641

10,897

10,496

14,348

Non-cash stock-based compensation

1,296

2,388

2,973

4,334

3,457

3,761

3,101

6,610

5,428

20,132

6,659

Depreciation and amortization

58

69

68

58

45

15

-

122

-

-

-

Depreciation and amortization

-

-

-

-

-

-

-

-

163

232

257

Non-cash net interest income

-

-

2

8

4

2

10

-342

-1,141

-1,252

-22

Changes in operating assets and liabilities:
Receivables

-

-

-

-

-

-

-

-

-7,114

4,812

2,104

Other current assets

23

49

-172

-86

87

-26

12

-105

214

-266

-132

Other non-current assets

-

-

12

-12

-

12

-352

-

-74

-1,585

440

Accounts payable

159

-130

129

-711

841

-272

84

-103

-643

-210

-899

Accrued development expense

621

-243

372

-867

869

-616

-288

15

656

-963

192

Accrued compensation and benefits

-3

-248

-26

-288

-29

-60

-141

-62

-797

574

-552

Other current liabilities

9

-

-

-

-

-3

-21

-

-

-

-

Deferred tax liabilities

-

-

-

-

-

-

-437

2

4

-

-

Deferred program fee revenue

-

-

-

-

-

-

-

-

-

5,000

-

Tax benefits from equity-based compensation plans

-

-

-

-

-

-

-

-

-

-

188

Excess tax benefits from equity-based compensation plans

-

-

-

-

-

-

-

57

-339

290

-9

Other current liabilities

-

-

-

-

-

-

-

-58

-15

-390

-344

Net cash used in operating activities

-

-

-

-

-9,053

-9,549

-6,947

-7,171

-260

-

-

Other non-current liabilities

-

-

-

-

-

-

-

-

-

-

4

Net cash used in operating activities

-2,514

-4,770

-8,237

-12,234

-

-

-

-

-

-143

-14,691

Cash flows from investing activities:
Purchases of property and equipment

18

-

-

75

195

80

-

-

-

-

-

Purchases of marketable securities

-

-

399

4,141

3,847

2,598

6,644

20,768

2,497

65,753

154,000

Sales of marketable securities

-

-

400

-

-

-

-

-

-

7,407

2,422

Maturities of marketable securities

-

-

2,100

2,050

3,850

3,850

12,300

38,390

62,400

110,809

48,350

Net cash provided (used in) investing activities

-

-

-

-

-192

1,172

5,656

17,622

59,903

-

-

Net cash provided by / (used in) investing activities

-18

-

2,101

-2,166

-

-

-

-

-

52,463

-103,228

Cash flows from financing activities:
Issuance costs from 2018 sale of common stock and warrants

60

-

-

-

-

-

-

-

-

-

-

Nondividend distribution

-

-

-

-

-

-

-

-33,995

-

-85,691

-

Excess tax benefits from equity-based compensation plans

-

-

-

-

-

-

-

57

-339

290

-9

Proceeds from sale of common stock and warrants, net

-

14,098

-

-

-

379

524

-302

9,042

2,085

564

Proceeds from exercise of common stock warrants, net

5,866

-

-

-

-

-

-

-

-

-

-

Cash used for statutory taxes for net exercise of Performance Awards

-

-

-

214

-

-

-

-

-

-

-

Deferred financing costs

-

-

-

70

46

-

-

-

-

-

-

Net cash used in financing activities

-

-

-

-

-46

379

524

-34,240

8,703

-

-

Net cash provided by / (used in) financing activities

5,806

14,098

-

-284

-

-

-

-

-

-83,316

555

Net increase / (decrease) in cash and cash equivalents

3,274

9,328

-

-

-

-

-

-

-

-

-

Net (decrease) / increase in cash and cash equivalents

-

-

-6,136

-14,684

-9,291

-7,998

-767

-23,789

68,346

-30,996

-117,364

Cash received for income taxes

-

-

-

-

-

-

-

-

-

3,765

1,177